Scancell Holdings plc (LSE:SCLP) has released positive results from its Phase 2 SCOPE trial, indicating that iSCIB1+ combined with checkpoint inhibitors could become a new benchmark for advanced melanoma treatment. The trial demonstrated a progression-free survival rate of 78% at 11 months. The company is accelerating development for iSCIB1+, including regulatory engagement and potential partnerships, with randomized studies expected to begin in 2026.
Early data from the ModiFY trial also suggests that Modi-1 improves response rates in head and neck cancer. In addition, Scancell has strengthened its executive team and secured a second commercial license with Genmab, reinforcing its strategic direction and potential for future milestones.
While the company faces significant financial challenges, with no revenue and substantial losses, recent clinical successes and strategic initiatives provide optimism for future growth. Technical indicators show mixed trends, with some short-term bullish momentum, though overbought conditions advise caution. Valuation remains unattractive due to ongoing financial pressures.
About Scancell Holdings
Scancell Holdings plc is a clinical-stage biotechnology company developing off-the-shelf active immunotherapies aimed at generating safe, durable tumor-specific immunity. Its lead product, iSCIB1+, from the DNA ImmunoBody® platform, shows promise in treating advanced melanoma. Another key therapy, Modi-1, from the Moditope® platform, is being evaluated for multiple solid tumors. The company has also launched GlyMab Therapeutics Ltd. to develop high-affinity GlyMab® antibodies targeting tumor-specific glycans.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply